Viberzi (Eluxadoline) Patent Expiration, LOE Window & CMS Spending
Viberzi (Eluxadoline) by AbbVie: FDA Orange Book core substance LOE 2029-05-27 (last listed 2033-03-14), 0 AB generics, $73.9M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | AbbVie |
| FDA Application & Pathway | N206940 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2029-05-27 |
| Last Listed Patent or Exclusivity Date | 2033-03-14 |
| Orange Book Patents (*PED Extensions) | 14 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $73.9M |
| 2024 Medicare Part D Spend | $59.2M |
| 2024 Medicaid Spend | $14.6M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.